[go: up one dir, main page]

WO2009060608A1 - Ｓｄｆ－１を含有してなる徐放性組成物 - Google Patents

Ｓｄｆ－１を含有してなる徐放性組成物 Download PDF

Info

Publication number
WO2009060608A1
WO2009060608A1 PCT/JP2008/003204 JP2008003204W WO2009060608A1 WO 2009060608 A1 WO2009060608 A1 WO 2009060608A1 JP 2008003204 W JP2008003204 W JP 2008003204W WO 2009060608 A1 WO2009060608 A1 WO 2009060608A1
Authority
WO
WIPO (PCT)
Prior art keywords
sdf
sustained release
composition
release composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003204
Other languages
English (en)
French (fr)
Inventor
Yasuhiko Tabata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to EP08847868A priority Critical patent/EP2218459B1/en
Priority to JP2009539954A priority patent/JP5248519B2/ja
Priority to US12/741,694 priority patent/US8435953B2/en
Priority to AT08847868T priority patent/ATE543507T1/de
Priority to ES08847868T priority patent/ES2378918T3/es
Publication of WO2009060608A1 publication Critical patent/WO2009060608A1/ja
Anticipated expiration legal-status Critical
Priority to US13/771,511 priority patent/US9107953B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

　本発明の課題は、ＳＤＦ－１含有徐放性組成物の提供にある。本発明は、（１）ＳＤＦ－１と、（２）カルボキシル基および／またはスルホ基を有する修飾ゼラチンからなるハイドロゲルとを含有してなる徐放性組成物を提供する。該組成物は、生体内にて血管前駆細胞の集積を促すケモカインであるＳＤＦ－１を持続的に放出することができるので、種々の剤形の医薬組成物として、例えば、虚血性疾患や骨疾患の治療および／または症状進展抑制剤として使用可能である。
PCT/JP2008/003204 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物 Ceased WO2009060608A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08847868A EP2218459B1 (en) 2007-11-07 2008-11-06 Sustained release composition containing sdf-1
JP2009539954A JP5248519B2 (ja) 2007-11-07 2008-11-06 Ｓｄｆ−１を含有してなる徐放性組成物
US12/741,694 US8435953B2 (en) 2007-11-07 2008-11-06 Sustained release composition containing SDF-1
AT08847868T ATE543507T1 (de) 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
ES08847868T ES2378918T3 (es) 2007-11-07 2008-11-06 Composición de liberación sostenida que contiene SDF-1
US13/771,511 US9107953B2 (en) 2007-11-07 2013-02-20 Sustained release composition containing SDF-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-289598 2007-11-07
JP2007289598 2007-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/741,694 A-371-Of-International US8435953B2 (en) 2007-11-07 2008-11-06 Sustained release composition containing SDF-1
US13/771,511 Division US9107953B2 (en) 2007-11-07 2013-02-20 Sustained release composition containing SDF-1

Publications (1)

Publication Number Publication Date
WO2009060608A1 true WO2009060608A1 (ja) 2009-05-14

Family

ID=40625516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003204 Ceased WO2009060608A1 (ja) 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物

Country Status (6)

Country Link
US (2) US8435953B2 (ja)
EP (1) EP2218459B1 (ja)
JP (1) JP5248519B2 (ja)
AT (1) ATE543507T1 (ja)
ES (1) ES2378918T3 (ja)
WO (1) WO2009060608A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821027B2 (en) 2011-08-23 2017-11-21 Mochida Pharmaceutical Co., Ltd. Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
JP2020512338A (ja) * 2017-03-30 2020-04-23 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
CN113144283A (zh) * 2021-04-26 2021-07-23 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
CA2838155C (en) * 2011-06-07 2021-10-19 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
CA2946761C (en) 2014-05-08 2023-08-22 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
ES2822924T3 (es) * 2014-09-26 2021-05-05 Helixmith Co Ltd Composición para prevenir o tratar una enfermedad arterial periférica utilizando el factor de crecimiento de hepatocitos y el factor 1a derivado de células del estroma
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
WO2019032930A1 (en) * 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
WO2024220980A2 (en) * 2023-04-20 2024-10-24 The Schepens Eye Research Institute, Inc. Dscam inhibitory nucleic acids and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (en) 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
WO2003007982A1 (fr) 2001-07-18 2003-01-30 Yasuhiko Tabata Preparations d'hydrogel hgf a liberation prolongee
WO2004030691A1 (ja) * 2002-10-04 2004-04-15 Medgel Corporation Ｎｋ４を含有する徐放性製剤
WO2005120549A2 (en) * 2004-06-07 2005-12-22 Conor Medsystems, Inc. Local delivery of growth factors for stem cell transplantation
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
WO2007080898A1 (ja) * 2006-01-10 2007-07-19 Medgel Corporation 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566798B1 (fr) * 1984-06-27 1986-12-12 Centre Nat Rech Scient Membrane porteuse de la luciferase pour le dosage de l'atp et son procede de production
US6297337B1 (en) * 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
GB0201674D0 (en) * 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (en) 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
WO2003007982A1 (fr) 2001-07-18 2003-01-30 Yasuhiko Tabata Preparations d'hydrogel hgf a liberation prolongee
WO2004030691A1 (ja) * 2002-10-04 2004-04-15 Medgel Corporation Ｎｋ４を含有する徐放性製剤
WO2005120549A2 (en) * 2004-06-07 2005-12-22 Conor Medsystems, Inc. Local delivery of growth factors for stem cell transplantation
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
WO2007080898A1 (ja) * 2006-01-10 2007-07-19 Medgel Corporation 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. 19, 1998, pages 1781 - 9
CIRCULATION, vol. 109, 2004, pages 2454 - 2461
KOHEI MIYAO: "Practical Drug Delivery Systems", MEDICINE AND DRUG JOURNAL, 1986
LANCET, vol. 362, 2003, pages 697 - 703
NATURE MEDICINE, vol. 10, no. 8, 2004, pages 858 - 864

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821027B2 (en) 2011-08-23 2017-11-21 Mochida Pharmaceutical Co., Ltd. Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
JP2020512338A (ja) * 2017-03-30 2020-04-23 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
JP2023015227A (ja) * 2017-03-30 2023-01-31 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
CN113144283A (zh) * 2021-04-26 2021-07-23 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用
CN113144283B (zh) * 2021-04-26 2022-06-28 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用

Also Published As

Publication number Publication date
US20130243824A1 (en) 2013-09-19
US8435953B2 (en) 2013-05-07
JPWO2009060608A1 (ja) 2011-03-17
ATE543507T1 (de) 2012-02-15
US9107953B2 (en) 2015-08-18
JP5248519B2 (ja) 2013-07-31
EP2218459B1 (en) 2012-02-01
EP2218459A1 (en) 2010-08-18
US20100267612A1 (en) 2010-10-21
EP2218459A4 (en) 2011-06-01
ES2378918T3 (es) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2009060608A1 (ja) Ｓｄｆ－１を含有してなる徐放性組成物
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
EP4245299A3 (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
MX2009005148A (es) Aptamero contra midcina, y uso del mismo.
WO2008052033A3 (en) Ibuprofen composition
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
MX2009014193A (es) Preparacion farmaceutica solida que comprende benzazepinas y metodo de produccion de la misma.
EP4527855A3 (en) Stable igg4 based binding agent formulations
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
NZ591408A (en) Paracetamol and Calcium carbonate composition
WO2008078109A3 (en) Medicament
IL198294A0 (en) A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
WO2005054446A3 (en) Use of polysulphated alginate in cellular matrices
WO2005002553A3 (en) Fluconazole capsules with improved release
EA200900531A1 (ru) Фармацевтические составы
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847868

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539954

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12741694

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008847868

Country of ref document: EP